Diagnostic value of lnc-RNAs TINCR, GC1 and AFAP1-AS1 in gastric cancer differentiation from healthy people.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-08-01 Epub Date: 2025-08-05 DOI:10.1080/17520363.2025.2542112

Pouneh Pourfarzam, Mohammad Bagher Khademerfan, Ramin Shakeri, Reza Ghanbari, Asaad Azarnezhad

{"title":"Diagnostic value of lnc-RNAs TINCR, GC1 and AFAP1-AS1 in gastric cancer differentiation from healthy people.","authors":"Pouneh Pourfarzam, Mohammad Bagher Khademerfan, Ramin Shakeri, Reza Ghanbari, Asaad Azarnezhad","doi":"10.1080/17520363.2025.2542112","DOIUrl":null,"url":null,"abstract":"Aims and background: Gastric cancer is a significant health challenge globally, necessitating the identification of novel biomarkers for improved diagnosis. Our study aimed to address this gap by investigating the diagnostic potential a set of long non-coding RNAs (lncRNAs) in gastric cancer patients compared to healthy controls.Materials and methods: We conducted a retrospective case-control analysis involving 256 participants, including 128 gastric cancer patients and 128 healthy individuals. Alongside the measurement of serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19.9), the plasma expression profiling of eight lnc-RNAs was performed in the selected samples.Results: Our findings revealed significant alterations in CEA and CA19.9 levels in gastric cancer patients compared to controls (p < 0.05). Moreover, upregulated expression of lncRNAs, including HOTIP, BANCR, ZFAS1, TINCR, GC1, and AFAP1-AS1, were all observed in gastric cancer patients (p < 0.05). Excluding lncUGC1 and FAM49B-AS, ROC curve analysis demonstrated the diagnostic potential of lncRNAs in gastric cancer detection, with notable specificity and sensitivity.Conclusion: Our study disclosed the diagnostic utility of plasma HOTIP, BANCR, ZFAS1, TINCR, GC1, and AFAP1-AS1 lncRNAs as appropriate diagnostic biomarkers for gastric cancer. The identification of dysregulated lncRNAs offers promising avenues for noninvasive diagnostic assessment in gastric cancer.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"757-767"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416196/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2542112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims and background: Gastric cancer is a significant health challenge globally, necessitating the identification of novel biomarkers for improved diagnosis. Our study aimed to address this gap by investigating the diagnostic potential a set of long non-coding RNAs (lncRNAs) in gastric cancer patients compared to healthy controls.

Materials and methods: We conducted a retrospective case-control analysis involving 256 participants, including 128 gastric cancer patients and 128 healthy individuals. Alongside the measurement of serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19.9), the plasma expression profiling of eight lnc-RNAs was performed in the selected samples.

Results: Our findings revealed significant alterations in CEA and CA19.9 levels in gastric cancer patients compared to controls (p < 0.05). Moreover, upregulated expression of lncRNAs, including HOTIP, BANCR, ZFAS1, TINCR, GC1, and AFAP1-AS1, were all observed in gastric cancer patients (p < 0.05). Excluding lncUGC1 and FAM49B-AS, ROC curve analysis demonstrated the diagnostic potential of lncRNAs in gastric cancer detection, with notable specificity and sensitivity.

Conclusion: Our study disclosed the diagnostic utility of plasma HOTIP, BANCR, ZFAS1, TINCR, GC1, and AFAP1-AS1 lncRNAs as appropriate diagnostic biomarkers for gastric cancer. The identification of dysregulated lncRNAs offers promising avenues for noninvasive diagnostic assessment in gastric cancer.

查看原文本刊更多论文

lnc- rna TINCR、GC1和AFAP1-AS1在健康人胃癌分化中的诊断价值。

目的和背景：胃癌是全球性的重大健康挑战，需要鉴定新的生物标志物来改善诊断。我们的研究旨在通过研究一组长链非编码rna （lncRNAs）在胃癌患者中与健康对照组相比的诊断潜力来解决这一空白。材料与方法：采用回顾性病例对照分析，共纳入256例受试者，其中胃癌患者128例，健康人128例。在测定血清癌胚抗原（CEA）和碳水化合物抗原19-9 （CA19.9）水平的同时，对所选样本进行8种lnc- rna的血浆表达谱分析。结论：我们的研究揭示了血浆HOTIP、BANCR、ZFAS1、TINCR、GC1和AFAP1-AS1 lncRNAs作为胃癌诊断的合适生物标志物的诊断价值。失调lncrna的鉴定为胃癌的无创诊断评估提供了有希望的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.